At Securitas Biosciences, we bridge the gap between cutting-edge scientific research and practical, real-world applications. Our mission is to transform groundbreaking biotech discoveries into viable, market-ready solutions that address the world’s most pressing challenges. We strive to lead in startup creation through a pioneering approach that emphasizes scientific excellence, diversity, and inclusion. Our vision is to cultivate a thriving biotech ecosystem where innovation flourishes, driving forward advancements in medical and biotechnological science to benefit communities globally.
We focus on developing bioactive compounds and therapeutic agents that stimulate tissue growth and regeneration, both in vivo (within the body) and ex vivo (outside the body in controlled environments). These innovative treatments leverage the body's innate healing mechanisms to restore function and repair damaged or degenerated tissues. By harnessing cellular processes such as stem cell activation, extracellular matrix production, and growth factor modulation, regenerative medicine holds the potential to treat a wide range of conditions, from chronic degenerative diseases to acute injuries, offering transformative solutions that go beyond symptom management to address the root causes of tissue dysfunction.
Our Synthetic Biology area focuses on re-designing and engineering biological systems to create innovative products across various industries. By utilizing advanced genetic tools and techniques, we develop organisms with novel capabilities that can produce valuable natural compounds or bio-based products. This approach enables the creation of sustainable solutions in areas such as biomanufacturing, pharmaceuticals, and agriculture, driving advancements in fields like bio-based drug development, industrial biotechnology, and environmental applications. Our work in synthetic biology is at the forefront of transforming scientific discoveries into scalable, commercially viable products with real-world impact.
Our NanoBiotechnology division focuses on developing advanced technologies that combine nanotechnology and biotechnology to create innovative therapeutic solutions. This includes the design and implementation of delivery systems for both small molecules and biologics, improving precision and effectiveness in targeted drug delivery. We also specialize in the development of viral vectors for cutting-edge treatments such as gene therapy, oncolytics, and vaccines, as well as Extracellular Vesicles (EV)-based therapies, which leverage natural vesicle systems for therapeutic applications. Additionally, this division is pioneering the creation of biopolymers with therapeutic potential, offering versatile applications in tissue engineering and regenerative medicine.
Our Precision Medicine division is focused on developing cutting-edge products and services that personalize healthcare. A key area of our work involves the creation of molecular signatures for the early detection and prediction of diseases that are difficult to diagnose in their early stages. We also design and validate companion diagnostic tests to guide the use of existing therapies, ensuring that treatments are tailored to the individual patient’s genetic profile. Additionally, our division develops and scales molecular tests for both common and rare diseases, providing clinicians with accurate and actionable data to improve patient outcomes.
Our Small Molecule Development division is dedicated to discovering and optimizing new drug candidates using an integrated approach. We utilize computational techniques such as Artificial Intelligence (AI), Machine learning (ML), and Molecular Dynamics (MD) to accelerate the discovery and optimization of novel therapeutics. This is complemented by medicinal chemistry, including organic synthesis and molecular characterization, to refine and validate promising candidates. Our expertise extends to formulation development, ensuring that new compounds are optimized for clinical application. Additionally, we employ advanced biochemical and biophysical tools to study interactions between small molecules and biological targets, facilitating the development of highly effective and targeted therapies. This comprehensive process allows us to create innovative solutions for a wide range of diseases.
The companies we build are disruptive on a global scale. We validate the science and the market supporting each opportunity. In alliance with renowned research, medical, and manufacturing institutions in South America, we are setting the stage to become a LatAm biotech reference.
Securitas Biosciences Group is a Venture Studio focused on life sciences.
Join us in Boston! 
This event will feature our CEO & Co-Founder, Matías Vidal, and VP of Medicinal Chemistry, Dr. Mariela Bollini, as they present Securitas Biosciences' vision of advancing biotech innovation across Latin America and the U.S.
Register now to learn more about our cutting-edge work and how we’re building a global biotech ecosystem!
Location: 245 Main Street, Cambridge, MA
In partnership with Latinos in Bio
A wonderful serenity has taken possession of my entire soul, like these sweet mornings of spring which I enjoy with my whole heart. I am alone, and feel the charm of existence in this spot, which was created for the bliss of souls like mine. I am so happy
A wonderful serenity has taken possession of my entire soul, like these sweet mornings of spring which I enjoy with my whole heart. I am alone, and feel the charm of existence in this spot, which was created for the bliss of souls like mine. I am so happy
A wonderful serenity has taken possession of my entire soul, like these sweet mornings of spring which I enjoy with my whole heart. I am alone, and feel the charm of existence in this spot, which was created for the bliss of souls like mine. I am so happy
